Evaluation of Endoglin (CD105) expression in pediatric rhabdomyosarcoma

[1] Sorensen PH(2002)PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children’s oncology group J Clin Oncol 20 2672-2679

[2] Lynch JC(2010)Outcomes in paediatric metastatic rhabdomyosarcoma: results of the International Society of Paediatric Oncology (SIOP) study MMT-98 Eur J Cancer 46 1588-1595

[3] Qualman SJ(2006)Angiogenesis and cancer: a cross-talk between basic science and clinical trials (the “do ut des” paradigm) Crit Rev Oncol Hematol 59 40-50

[4] McDowell HP(2008)Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program Pediatr Blood Cancer 51 42-48

[5] Foot AB(2011)Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor Clin Cancer Res 17 5656-5667

[6] Ellershaw C(2012)Initial testing of the multitargeted kinase inhibitor pazopanib by the pediatric preclinical testing program Pediatr Blood Cancer 59 586-588

[7] Machin D(2013)Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors Clin Cancer Res 19 236-246

[8] Giraud C(2013)Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a children's oncology group phase I consortium report J Clin Oncol 31 3034-3043

[9] Bergeron C(1997)Comparative evaluation of angiogenesis assessment with anti-factor-VIII and anti-CD31 immunostaining in non-small cell lung cancer Clin Cancer Res 3 2485-2492

[10] de Castro JG(1995)Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors Breast Cancer Res Treat 36 169-180

[1] Sorensen PH(2002)PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children’s oncology group J Clin Oncol 20 2672-2679

[2] Lynch JC(2010)Outcomes in paediatric metastatic rhabdomyosarcoma: results of the International Society of Paediatric Oncology (SIOP) study MMT-98 Eur J Cancer 46 1588-1595

[3] Qualman SJ(2006)Angiogenesis and cancer: a cross-talk between basic science and clinical trials (the “do ut des” paradigm) Crit Rev Oncol Hematol 59 40-50

[4] McDowell HP(2008)Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program Pediatr Blood Cancer 51 42-48

[5] Foot AB(2011)Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor Clin Cancer Res 17 5656-5667

[6] Ellershaw C(2012)Initial testing of the multitargeted kinase inhibitor pazopanib by the pediatric preclinical testing program Pediatr Blood Cancer 59 586-588

[7] Machin D(2013)Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors Clin Cancer Res 19 236-246

[8] Giraud C(2013)Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a children's oncology group phase I consortium report J Clin Oncol 31 3034-3043

[9] Bergeron C(1997)Comparative evaluation of angiogenesis assessment with anti-factor-VIII and anti-CD31 immunostaining in non-small cell lung cancer Clin Cancer Res 3 2485-2492

[10] de Castro JG(1995)Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors Breast Cancer Res Treat 36 169-180